First Max Planck Center for Regenerative Biomedicine opens in China
December 21, 2016
The development of iPS technology has opened new doors for regenerative biomedicine, which has experienced a major boost as a result. The technology enables patients’ own cells to be reversed to an embryonic state, reproduced on an almost infinite scale and transformed into all of the different types of cells found in the body. This means that researchers can now study diseases and develop new drugs in the petri dish. The work of the new Max Planck Center is focused on brain, cardiac and lung cells.
“Through the new Max Planck Center we can make crucial progress in the development of iPS technology and optimize differentiation processes in nerve, cardiac and lung cells so that they provide the best possible disease models for study in the petri dish. These are crucial preconditions for the advancement of regenerative medicine and drug research,” says Hans Schöler, Director at the Max Planck Institute for Molecular Biomedicine in Münster and one of the two Co-Directors of this first Max Planck Center in China.
On the German side, Thomas Braun and Werner Seeger, both Directors of the Max Planck Institute for Heart and Lung Research in Bad Nauheim, are involved in the research programme. Second director is Duanqing Pei from the Guangzhou Institutes of Biomedicine and Health of the Chinese Academy of Sciences, and their associated Hong Kong laboratory group.
“The Max Planck Center will be a hub for international cooperation with China and offer outstanding Asian scientists the opportunity to contribute their expertise in application-oriented stem cell research and regenerative biomedicine to the research in Germany,” says Hans Schöler explaining the advantages of the new Max Planck Center. “We hope that the new networking opportunities will enable us to carry out cutting-edge scientific research.”
iPS technology is at the heart of the research carried out at the new Max Planck Center. A great deal of work has been done on induced pluripotent stem cells since 2012. The advantage of this technology is that it enables the patient’s own cells to be reproduced on an almost infinite scale and transformed into all of the different types of cells in the body. As a cell model for diseases in the petri dish, iPS cells can provide insights into both the emergence of diseases and potential treatment mechanisms.
The researchers at the new Max Planck Center would like to study in detail how nerve, cardiac muscle and lung cells can be generated in the petri dish, as good differentiation protocols are essential for iPS-based disease research and the associated potential drug development. Another objective is to transfer the findings of the iPS research to regenerative medicine. This involves completing the leap from the petri dish to the damaged tissue, studying mechanisms in the tissue that can stimulate cells to regenerate, and examining how iPS cells can be used for transplants. The scientists also aim to identify regulatory molecules that could offer therapeutic benefits for different cardiac and lung diseases.